WING CHI HLDGS (06080) Issues Profit Warning, Expects Interim Net Consolidated Loss Attributable to Shareholders of Not Less Than Approximately HK$12.2 million
WING CHI HLDGS (06080) announced that the Group expects to record a net consolidated loss attributable to owners of the Company of not less than approximately HK$12.2 million for the six months ended September 30, 2026 (the Period), compared to a net loss attributable to owners of the Company of approximately HK$12.9 million for the six months ended September 30, 2025.
WING CHI HLDGS (06080) announces that the Group expects to record a net consolidated loss attributable to owners of the Company of not less than approximately HK$12.2 million for the six months ended 30 September 2026 (the Period), as compared to a net loss attributable to owners of the Company of approximately HK$12.9 million for the six months ended 30 September 2025.
The Board considers that the net loss is mainly attributable to the following factors: (i) the decrease in the number and revenue of new projects due to the current property market conditions and the broad economic cycle, as well as the completion of large-scale projects last year, resulting in a decrease in revenue recognized during the Period;
(ii) intensified competitive pressure in the foundation and site formation industry, which is attributable to the general pressure on contract prices for both public and private sector projects, coupled with the weak overall economy; and (iii) projects failing to achieve expected profit margins due to increasingly stringent revenue approval requirements imposed by customers.
Related Articles

Muyuan Foods Group (02714) repurchased 65,700 shares on November 4 for HK$2.5189 million.

Shanghai Fosun Pharmaceutical (02196): Phase III clinical trial of FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria initiated in China

TONGRENTANGCARE (02667) received an increase of 100,000 shares by a company executive.
Muyuan Foods Group (02714) repurchased 65,700 shares on November 4 for HK$2.5189 million.

Shanghai Fosun Pharmaceutical (02196): Phase III clinical trial of FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria initiated in China

TONGRENTANGCARE (02667) received an increase of 100,000 shares by a company executive.






